Physician
Georgescu, Teodor
Georgescu, Teodor was paid $4.71M by Medicaid between Jan 2018 and Mar 2023, across 48 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 23% of everything it billed.
33Billing provider infoGEORGESCU, TEODOR
NEW BEDFORD, MA 02740
NEW BEDFORD, MA 02740
33aNPI1417989955assigned 07/07/2006
33bProvider typePediatrics Physician
28Total paid$4.71M
24GClaims128,989
24DCodes billed48
24AFirst – last monthJan 2018 – Mar 2023
Compared with peers
Next to other Pediatrics Physician providers in Massachusetts
Rank by total paid#8 of 1,273
Median peer was paid$24K
This provider vs. median197×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 25,049 | $851K | |
| 2019 | 31,659 | $1.10M | |
| 2020 | 23,275 | $888K | |
| 2021 | 25,919 | $996K | |
| 2022 | 18,415 | $699K | |
| 2023 | 4,672 | $172K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 23% | 19,187 | 17,348 | $1.10M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 13% | 6,364 | 6,128 | $597K |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | 10% | 14,737 | 12,030 | $473K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | 7.2% | 4,102 | 4,102 | $341K |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 7.2% | 4,032 | 4,031 | $337K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | 6.2% | 3,237 | 3,236 | $294K |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | 5.1% | 3,085 | 3,062 | $241K |
| 92588 | 3.9% | 3,694 | 3,694 | $184K | |
| 90461 | 3.2% | 4,488 | 4,448 | $152K | |
| 99215 | Doctor's office visit, returning patient (complex)Prolong outpt/office vis | 2.9% | 1,196 | 1,184 | $138K |
| S0302 | Completed early periodic screening diagnosis and treatment (epsdt) service (list in addition to code for appropriate evaluation and management service) | 2.7% | 14,047 | 14,029 | $127K |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | 2.0% | 9,222 | 9,046 | $95K |
36 more codes
| 96127 | 1.4% | 6,465 | $66K | |
| 99173 | 1.3% | 2,879 | $63K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.3% | 7,806 | $59K |
| 95930 | 1.1% | 489 | $53K | |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 463 | $43K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 3,349 | $41K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,344 | $39K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,344 | $39K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 1,104 | $37K |
| 83655 | <1% | 2,620 | $31K | |
| 86003 | <1% | 244 | $26K | |
| 87081 | <1% | 2,610 | $17K | |
| 94010 | <1% | 538 | $16K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 1,213 | $15K |
| 82465 | <1% | 3,394 | $15K | |
| 99188 | <1% | 561 | $15K | |
| 0071A | <1% | 167 | $8K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 275 | $6K |
| 0072A | <1% | 122 | $6K | |
| 81002 | <1% | 1,722 | $4K | |
| 0001A | <1% | 91 | $4K | |
| 82947 | <1% | 1,019 | $4K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 447 | $4K |
| 81025 | <1% | 542 | $4K | |
| 99050 | <1% | 205 | $3K | |
| 92555 | <1% | 163 | $3K | |
| 0002A | <1% | 56 | $3K | |
| 99383 | <1% | 14 | $1K | |
| 87070 | <1% | 92 | $1K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 64 | $991.90 |
| 93000 | <1% | 43 | $580.93 | |
| 96161 | <1% | 68 | $262.48 | |
| 87807 | <1% | 21 | $248.01 | |
| 94760 | <1% | 13 | $32.89 | |
| S0119 | Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) | <1% | 25 | $32.00 |
| J7611 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 1 mg | <1% | 26 | $8.90 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.